文献速递炎症性肠病消化道肿瘤与早癌消化内镜

推进炎症性肠病相关结直肠癌管理:分子洞见与内镜突破迈向精准医学

Advancing Inflammatory Bowel Disease-Driven Colorectal Cancer Management: Molecular Insights and Endoscopic Breakthroughs Towards Precision Medicine.
PubMed 文献 · Clin Gastroenterol Hepatol · 2025-07-22

本文综述炎症性肠病(IBD)相关结直肠癌的发病机制新概念,包括饮食、微生物组改变与肠屏障功能障碍的相互作用,并介绍超高清放大内镜、空间生物学平台、微小RNA与液体活检等诊断评估新技术,以及人工智能、组学整合与纳米技术治疗等未来方向。

要点

  • IBD相关结直肠癌仍是重要临床问题,尽管IBD管理进步使CRC发病率下降。
  • 饮食、微生物组改变与肠屏障功能障碍在结肠炎相关癌变中相互作用。
  • 超高清放大内镜、空间生物学与液体活检等新技术推动精准诊疗。

核心结论

  • IBD相关CRC管理的未来将采用整体、多整合方法,结合人工智能驱动诊断、组学数据整合、内镜与外科创新及纳米技术治疗,以增强精准医学、促进保留器官策略、改善诊断与个体化癌症治疗,并有望降低CRC风险。

研究设计与样本

  • 本文为综述,探讨炎症性肠病相关结直肠癌的发病机制新概念、诊断评估新技术及未来管理方向。

主要发现

  • 尽管IBD管理进步使CRC发病率下降,CRC仍是IBD的严重并发症,显著增加死亡率和医疗负担。
  • 饮食、微生物组改变与肠屏障功能障碍在CRC进展中存在复杂相互作用。
  • 超高清放大内镜和新的空间生物学平台可用于评估肠屏障完整性和分子生物标志物如微小RNA和液体活检。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Colorectal cancer (CRC) is a serious complication of inflammatory bowel disease (IBD), significantly contributing to increased mortality and health care burden. Although advances in IBD management have led to a decline in CRC incidence, it remains a major clinical concern. Recent breakthroughs in advanced imaging, molecular diagnostics, and artificial intelligence are poised to revolutionize precision medicine in IBD-associated CRC, potentially reducing neoplastic risk and improving patient outcomes. This review explores emerging concepts in colitis-associated cancer pathogenesis, including the intricate interplay between diet, microbiome alterations, and intestinal barrier dysfunction in CRC progression. Additionally, it highlights cutting-edge diagnostic and assessment techniques, such as ultra-high magnification endoscopy, and new spatial biology platforms for assessing intestinal barrier integrity and molecular biomarkers, such as microRNAs and liquid biopsy. The future of IBD-related CRC management will incorporate a holistic, multi-integrated approach, combining artificial intelligence-driven diagnostics, omics data integration, endoscopic and surgical innovations, and nanotechnology-based therapies. This paradigm shift aims to enhance precision medicine, promoting organ-sparing approaches, improved diagnostics, and personalized cancer treatment with the potential to reduce CRC risk.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Iacucci M, Nardone OM, Ditonno I, et al. Advancing Inflammatory Bowel Disease-Driven Colorectal Cancer Management: Molecular Insights and Endoscopic Breakthroughs Towards Precision Medicine. Clin Gastroenterol Hepatol. 2025. PMID: 40706730. doi:10.1016/j.cgh.2025.06.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。